Harrow Health (HROW) Company Overview

Harrow's 11.875% Senior Notes due 2027 are attractive baby bonds with a healthy leverage percentage of 13.8%, indicating strong creditworthiness and low debt. Harrow funds operations through product sales, not debt or frequent equity raises, showcasing a robust financial position and sustainable business model. VEVYE, IHEEZO, and Triesence show significant growth potential, with Triesence addressing supply chain issues and justified price hikes, ensuring strong future demand.

Harrow's relaunch of Triesence, a preservative-free corticosteroid, addresses a critical unmet need in ophthalmology, offering safer and more effective treatment options for eye care professionals. Triesence's unique formulation and absence of preservatives make it superior to alternatives like Kenalog, despite its higher price point and previous supply chain issues. Harrow's acquisition and relaunch of Triesence, with 39,000 units available, positions the company for significant market growth, targeting over 500,000 units annually.

NASHVILLE, Tenn.--(BUSINESS WIRE)---- $HROW--Harrow (Nasdaq: HROW), a leading North American eyecare pharmaceutical company, today announced that management will participate in the following three investor conferences: Craig-Hallum 15th Annual Alpha Select Conference (Sheraton New York Times Square Hotel) November 19, 2024 1x1 Meetings Only BTIG 4th Annual Ophthalmology Day (Virtual) December 2, 2024 1x1 Virtual Meetings Only Piper Sandler 36th Annual Healthcare Conference (The Lotte New York Palace) Dec.

Harrow, Inc. (NASDAQ:HROW ) Q3 2024 Earnings Conference Call November 14, 2024 8:30 AM ET Company Participants Jamie Webb - Director, Communications & Investor Relations Mark Baum - CEO Andrew Boll - CFO Conference Call Participants Chase Knickerbocker - Craig Hallum Brooks O'Neil - Lake Street Capital Markets Jeffrey Cohen - Ladenburg Thalmann & Company Mayank Mamtani - B. Riley Securities Operator Good morning, and welcome to Harrow's Third Quarter 2024 Earnings Conference Call.

Harrow (HROW) came out with a quarterly loss of $0.12 per share versus the Zacks Consensus Estimate of a loss of $0.05. This compares to loss of $0.09 per share a year ago.

NASHVILLE, Tenn.--(BUSINESS WIRE)---- $HROW--Harrow (Nasdaq: HROW), a leading North American eyecare pharmaceutical company, announced results for the third quarter and nine months ended September 30, 2024. The Company also posted its third quarter Letter to Stockholders and corporate presentation to the “Investors” section of its website, harrow.com. The Company encourages all Harrow stockholders to review these documents, which provide additional details concerning the historical quarterly period and f.

Harrow Inc. experienced a brief 20% stock drop in October but quickly recovered, showing resilience despite recent revenue channel underperformance. HROW's new branded pharmaceutical products, especially VEVYE, are driving a diversified revenue stream, with VEVYE showing exceptional growth and market penetration since its late 2023 launch. VEVYE's strong refill rates and expanding prescriber base indicate significant patient benefits and long-term revenue potential, supported by a patent extending to 2039.

Harrow (HROW) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

HROW, ORLA and SWDBY made it to the Zacks Rank #1 (Strong Buy) momentum stocks list on November 6, 2024.